Phase 4 N=79 Randomized Single-blind Treatment

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

Microlaryngoscopy · Rigid Bronchoscopy

Bottom Line

View on ClinicalTrials.gov: NCT03111121 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2025

Primary outcome: Primary: Time to Extubation After End of Procedure — 11.06; 10.36 Minutes

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Sugammadex (Drug); neostigmine (Drug); glycopyrrolate (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: West Virginia University
Primary completion: Jun 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Time to Extubation After End of Procedure	11.06; 10.36	—

Summary

Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure

Eligibility Criteria

Inclusion Criteria

Microlaryngoscopy or rigid bronchoscopy for vocal cord and tracheal procedures

Age 18 years or older,

ASA physical status I-III

Ability to give written informed consent.

Exclusion Criteria

Known or suspected neuromuscular disease/pre-existing weakness,

Creatinine clearance less than 30 ml/min

Bradycardia of less than 40 beats/min,

Pregnancy, breast feeding women

Known or suspected allergy to BRIDION® (sugammadex), neostigmine or rocuronium.

Patients with contraindications towards sugammadex, neostigmine or rocuronium

Patients included in another trial within the last 30 days

Patients with legal guardians or surrogate decision making

Patients who refuse to use non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days if receiving sugammadex.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03111121). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.